<code id='299E58FDA0'></code><style id='299E58FDA0'></style>
    • <acronym id='299E58FDA0'></acronym>
      <center id='299E58FDA0'><center id='299E58FDA0'><tfoot id='299E58FDA0'></tfoot></center><abbr id='299E58FDA0'><dir id='299E58FDA0'><tfoot id='299E58FDA0'></tfoot><noframes id='299E58FDA0'>

    • <optgroup id='299E58FDA0'><strike id='299E58FDA0'><sup id='299E58FDA0'></sup></strike><code id='299E58FDA0'></code></optgroup>
        1. <b id='299E58FDA0'><label id='299E58FDA0'><select id='299E58FDA0'><dt id='299E58FDA0'><span id='299E58FDA0'></span></dt></select></label></b><u id='299E58FDA0'></u>
          <i id='299E58FDA0'><strike id='299E58FDA0'><tt id='299E58FDA0'><pre id='299E58FDA0'></pre></tt></strike></i>

          Home / explore / comprehensive

          comprehensive


          comprehensive

          author:Wikipedia    Page View:9371

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In